Independent research in Eastern and Southern Africa identifies opportunities to improve effectiveness of Global Fund processes
In what has been hailed as a “breakthrough” and a “game changer,” a pricing agreement between the Bill and Melinda Gates Foundation and two generic drug companies will result in significant savings in the cost of antiretrovirals (ARVs). As a result of the agreement, starting in 2018 a state-of-the-art fixed dose combination ARV regimen will be available in 92 developing nations at a maximum cost of $75 per patient per year.
- The Bill and Melinda Gates Foundation yesterday announced a new pledge of $50 million for the Fund. This marks the third consecutive year in which Gates has given $50 million to the Fund. Although private foundations have a Global Fund board seat, no other foundation has ever given to the Fund, except for pro bono services and some very minor donations of a few thousand dollars.